MBX Biosciences, Inc. Common Stock (MBX) - Net Assets
Based on the latest financial reports, MBX Biosciences, Inc. Common Stock (MBX) has net assets worth $387.54 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($400.08 Million) and total liabilities ($12.54 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check MBX asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $387.54 Million |
| % of Total Assets | 96.87% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
MBX Biosciences, Inc. Common Stock - Net Assets Trend (2022–2024)
This chart illustrates how MBX Biosciences, Inc. Common Stock's net assets have evolved over time, based on quarterly financial data. Also explore how large is MBX Biosciences, Inc. Common Stock's balance sheet for the complete picture of this company's asset base.
Annual Net Assets for MBX Biosciences, Inc. Common Stock (2022–2024)
The table below shows the annual net assets of MBX Biosciences, Inc. Common Stock from 2022 to 2024. For live valuation and market cap data, see MBX stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $257.44 Million | +455.25% |
| 2023-12-31 | $-72.47 Million | -70.09% |
| 2022-12-31 | $-42.60 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to MBX Biosciences, Inc. Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 9448500000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $5.00K | 0.00% |
| Other Comprehensive Income | $55.00K | 0.02% |
| Other Components | $394.89 Million | 153.39% |
| Total Equity | $257.44 Million | 100.00% |
MBX Biosciences, Inc. Common Stock Competitors by Market Cap
The table below lists competitors of MBX Biosciences, Inc. Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Rami Levi
TA:RMLI
|
$1.34 Billion |
|
Derichebourg
PA:DBG
|
$1.34 Billion |
|
Shanghai Chengdi Constr Co
SHG:603887
|
$1.34 Billion |
|
Boai NKY Pharmaceuticals Ltd
SHE:300109
|
$1.34 Billion |
|
Hoist Finance AB
ST:HOFI
|
$1.34 Billion |
|
Wave Life Sciences Ltd
NASDAQ:WVE
|
$1.34 Billion |
|
Wuxi Longsheng Technology Co Ltd
SHE:300680
|
$1.34 Billion |
|
Guangdong Lyric Robot Automation Co Ltd
SHG:688499
|
$1.34 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in MBX Biosciences, Inc. Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -72,468,000 to 257,442,000, a change of 329,910,000.
- Net loss of 61,922,000 reduced equity.
- New share issuances of 238,042,000 increased equity.
- Other comprehensive income decreased equity by 5,000.
- Other factors increased equity by 153,795,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-61.92 Million | -24.05% |
| Share Issuances | $238.04 Million | +92.46% |
| Other Comprehensive Income | $-5.00K | -0.0% |
| Other Changes | $153.79 Million | +59.74% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares MBX Biosciences, Inc. Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.86x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-12-31 | $-1.34 | $29.78 | x |
| 2023-12-31 | $-2.28 | $29.78 | x |
| 2024-12-31 | $7.71 | $29.78 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently MBX Biosciences, Inc. Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -24.05%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.04x
- Recent ROE (-24.05%) is below the historical average (-8.02%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-21.87 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-25.32 Million |
| 2024 | -24.05% | 0.00% | 0.00x | 1.04x | $-87.67 Million |
Industry Comparison
This section compares MBX Biosciences, Inc. Common Stock's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| MBX Biosciences, Inc. Common Stock (MBX) | $387.54 Million | 0.00% | 0.03x | $1.34 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About MBX Biosciences, Inc. Common Stock
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, … Read more